Richardson AI, et al. - Researchers evaluated the data to estimate the significance of p53 expression in MYC extra copies (MYC-EC) lymphomas and CD99 expression in association to MYC status. They determined 122 individuals with diagnosed large B-cell lymphoma ie, 44 with MYC-negative; 29 with MYC-EC; 23 with MYC rearrangement; 22 with MYC and BCL2 rearrangements; 4 with MYC, BCL2, and BCL6 rearrangements. They noted a correlation between p53 expression and diffuse large B-cell lymphoma (DLBCL) with abnormal MYC status. They observed the adverse p53 prognostic impact only with MYC-rearranged lymphoma. They did not find any improvement in survival with high-intensity chemotherapy (dose-adjusted rituximab and etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin/rituximab and hyperfractionated cyclophosphamide-vincristine-doxorubicin-dexamethasone treatment) in subjects with MYC-EC and MYC-rearranged lymphoma when compared with rituximab-cyclophosphamide-hydroxydaunomycin-vincristine-prednisone therapy.